SCHEMBL177847

SCHEMBL177847

CCCOP(=O)(OCl)OCCC

nearest known ligand 0.50

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.50
TSHR P16473 2/20 0.43
ALDH1A1 P00352 1/20 0.42
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
TP53 P04637 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
LPAR3 Q9UBY5 3/20 0.33
LPAR1 Q92633 2/20 0.33
LPAR2 Q9HBW0 2/20 0.33
HPGD P15428 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4380221 0.95 CYP3A4 (0.50) CYP3A4TSHRALDH1A1MEN1KMT2A
SCHEMBL11213966 0.93 TSHR (0.52) CYP3A4TSHRALDH1A1MEN1KMT2A
SCHEMBL25170072 0.86 CYP3A4 (0.43) CYP3A4TSHRALDH1A1MEN1KMT2A
SCHEMBL1009658 0.86 CYP3A4 (0.43) CYP3A4TSHRALDH1A1MEN1KMT2A
SCHEMBL5850293 0.86 CYP3A4 (0.43) CYP3A4TSHRALDH1A1MEN1KMT2A
SCHEMBL29245227 0.86 CYP3A4 (0.43) CYP3A4TSHRALDH1A1MEN1KMT2A
SCHEMBL178129 0.85 CYP3A4 (0.73) CYP3A4TSHRLPAR3LPAR1LPAR2
Ammonia Solution, Strong SCHEMBL28664397 0.84 CYP3A4 (0.41) CYP3A4TSHRALDH1A1MEN1KMT2A
SCHEMBL178107 0.83 CYP3A4 (0.62) CYP3A4TSHRLPAR3LPAR1LPAR2
SCHEMBL104844 0.83 CYP3A4 (0.68) CYP3A4TSHRALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119350511-A Uranium thorium specific capture agent in complex solution system, synthesis method and application thereof 浙江创欣新材料有限公司 2025-01-24 CN claimed
CN-119350511-A Uranium thorium specific capture agent in complex solution system, synthesis method and application thereof 浙江创欣新材料有限公司 2025-01-24 CN disclosed
CN-117024658-A Phospholipid terminal functionalized rare earth isoprene rubber and preparation method and application thereof 海南天然橡胶产业集团股份有限公司 2023-11-10 CN disclosed
EP-3222624-B1 IMIDIC ACID COMPOUND HAVING DIVALENT ANION AND PROCESS FOR PRODUCING THE SAME CENTRAL GLASS CO LTD (JP) 2019-11-06 EP disclosed
US-10287165-B2 Imidic acid compound having divalent anion and process for producing the same CENTRAL GLASS CO., LTD. (JP) 2019-05-14 US disclosed
EP-2389348-B1 PROCESS FOR THE SYNTHESIS OF BETA GLYCEROL PHOSPHATE SIGMA ALDRICH CO LLC (US) 2017-11-15 EP disclosed
EP-3222624-A1 IMIDIC ACID COMPOUND HAVING DIVALENT ANION AND PROCESS FOR PRODUCING THE SAME Central Glass Co., Ltd. (JP) 2017-09-27 EP disclosed
US-20170267528-A1 IMIDIC ACID COMPOUND HAVING DIVALENT ANION AND PROCESS FOR PRODUCING THE SAME CENTRAL GLASS CO., LTD. (JP) 2017-09-21 US disclosed
US-8420848-B2 Process for the synthesis of beta glycerol phosphate SIGMA-ALDRICH CO. LLC (US) 2013-04-16 US disclosed
US-20120041222-A1 PROCESS THE SYNTHESIS OF BETA GLYCEROL PHOSPHATE SIGMA-ALDRICH CO. (US) 2012-02-16 US disclosed
US-5399577-A Lipoxygenase and cyclooxygenase inhibitor, antiasthma, antiinflammatory TAIHO PHARMACEUTICAL CO., LTD. (JP) 1995-03-21 US disclosed
EP-0633254-A1 NOVEL ISOXAZOLE DERIVATIVE AND SALT THEREOF TAIHO PHARMACEUTICAL CO., LTD. (JP) 1995-01-11 EP disclosed
EP-0376745-B1 Optical recording medium and process for the production thereof TOYO INK MFG CO (JP) 1994-12-07 EP disclosed
EP-0623603-A1 STYRENE DERIVATIVE AND SALTS THEREOF TAIHO PHARMACEUTICAL CO., LTD. (JP) 1994-11-09 EP disclosed
US-5182284-A Antiasthmatic agent, antiallergen, antiinflammatory agent TAIHO PHARMACEUTICAL CO., LTD. (JP) 1993-01-26 US disclosed
EP-0465659-A1 PIPERAZINE COMPOUND, PRODUCTION THEREOF, AND MEDICINAL USE THEREOF TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) 1992-01-15 EP disclosed
US-4943681-A PHTHALOCYANINE COMPLEX, HIGH SENSITIVITY, LASERS TOYO INK MANUFACTURING CO., LTD. (JP) 1990-07-24 US disclosed
EP-0376745-A2 Optical recording medium and process for the production thereof TOYO INK MANUFACTURING CO., LTD. (JP) 1990-07-04 EP disclosed
US-4851399-A Isoquinoline derivatives and their use as anti-cancer agents GLAXO GROUP LIMITED (GB) 1989-07-25 US disclosed
US-4309422-A INSECTICIDES VELSICOL CHEMICAL CORPORATION (US) 1982-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170267528-A1 IMIDIC ACID COMPOUND HAVING DIVALENT ANION AND PROCESS FOR PRODUCING THE SAME CA2, CA6, CHRM1 CYP3A4 415/4885TSHR 929/4885ALDH1A1 975/4885
US-10287165-B2 Imidic acid compound having divalent anion and process for producing the same CA2, CA6, CHRM1 CYP3A4 415/4885TSHR 929/4885ALDH1A1 975/4885
US-20120041222-A1 PROCESS THE SYNTHESIS OF BETA GLYCEROL PHOSPHATE GK, GNPAT, AGPAT5 CYP3A4 1991/4885TSHR 4346/4885ALDH1A1 2072/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.